Skip to main content
Premium Trial:

Request an Annual Quote

GeneOhm to Acquire Infectio Diagnostic; Company Will Receive $12M VC Cash Infusion

NEW YORK, Oct. 21 (GenomeWeb News) - Microarray company GeneOhm Sciences will acquire Infectio Diagnostic in a stock swap expected to close in November, the firms said today.

 

The deal will be followed by a $12 million venture-capital investment supporting the combined company, said GeneOhm spokesman JC Kyrillos. He declined to disclose financial details of the transaction.

 

The investment will be made by Princeton, NJ-based Domain Associates; Stamford, Conn.-based Collinson, Howe and Lennox; and Boston-based CB Health. It will help support R&D, sales, and marketing , which will result in two diagnostic products based on GeneOhm's ePlex microarray platform. The technology will be released "in early 2005," said Kyrillos.

 

Initial products will include a microarray-based diagnostic for group-B streptococcus  and methicillin-resistant staphylococcus aureus, said Kyrillos. Additional ePlex multiplex infectious disease products based on Infectio Diagnostic technologies are expected in "early 2006," Kyrillos said.

 

Funding will be used to recruit a salesforce, as well as related sales and marketing expenses, he added. No layoffs will accompany the transaction.

 

Peter Klemm, CEO of GeneOhm, will remain in his position in the combined company, while Infectio Diagnostic President Jean Pierre Gayral will become president of the company's Canadian organization and senior vice president for infectious disease.

 

Infectio is based in Sainte-Foy, Canada.

The Scan

Study Finds Sorghum Genetic Loci Influencing Composition, Function of Human Gut Microbes

Focusing on microbes found in the human gut microbiome, researchers in Nature Communications identified 10 sorghum loci that appear to influence the microbial taxa or microbial metabolite features.

Treatment Costs May Not Coincide With R&D Investment, Study Suggests

Researchers in JAMA Network Open did not find an association between ultimate treatment costs and investments in a drug when they analyzed available data on 60 approved drugs.

Sleep-Related Variants Show Low Penetrance in Large Population Analysis

A limited number of variants had documented sleep effects in an investigation in PLOS Genetics of 10 genes with reported sleep ties in nearly 192,000 participants in four population studies.

Researchers Develop Polygenic Risk Scores for Dozens of Disease-Related Exposures

With genetic data from two large population cohorts and summary statistics from prior genome-wide association studies, researchers came up with 27 exposure polygenic risk scores in the American Journal of Human Genetics.